ENterogermina® (Bacillus Clausii) In the manaGeMent of diarrheA in Children
ENIGMA
Phase III Comparative Study to Assess the Efficacy and Safety of Oral Rehydration Therapy (ORT) in Combination With Spores of Bacillus Clausii (Enterogermina)Versus ORT Alone, Administered for 5 Days With the Treatment of Acute Diarrhea in Children.
1 other identifier
interventional
264
1 country
1
Brief Summary
Primary:
- To demonstrate the efficacy of Enterogermina® in reducing the duration of acute diarrhea in children Secondary:
- To evaluate the safety of Enterogermina® in acute diarrhea in Indian children
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at P50-P75 for phase_3
1 active site
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
Study Start
First participant enrolled
March 1, 2007
CompletedFirst Submitted
Initial submission to the registry
April 5, 2007
CompletedFirst Posted
Study publicly available on registry
April 6, 2007
CompletedPrimary Completion
Last participant's last visit for primary outcome
December 1, 2007
CompletedJanuary 21, 2009
January 1, 2009
9 months
April 5, 2007
January 20, 2009
Conditions
Outcome Measures
Primary Outcomes (2)
Reduction in duration of diarrhea
Throughout the treatment period
Incidence of adverse events
Throughout the study period
Secondary Outcomes (5)
Mean number of stools per day
Throughout the treatment period
Effect on consistency of stools
Throughtout the treatment period
Vomiting episodes per day
Throughout the treatment period
Requirement of unscheduled intravenous transfusion
Throughout the study period
Need for hospitalization
Throughout the treatment period
Study Arms (2)
1
ACTIVE COMPARATORAdministration of oral rehydration therapy with Bacillus clausii probiotic strain (1 vial twice daily, each vial containing 2 billion spores of Bacillus clausii)
2
PLACEBO COMPARATORAdministration of Oral rehydration therapy
Interventions
Eligibility Criteria
You may qualify if:
- Non hospitalised infants and children attending clinic/outpatients with acute diarrhea (\>3 liquid or watery stools occurring in a 24-hour period) of less than 48 hours duration
You may not qualify if:
- History of presence of blood, pus, or mucus in stools
- Severe dehydration (World Health Organization criteria)
- Severely malnourished patients
- Treatment with antibiotics, probiotics, or prebiotics within a period of 2 weeks before enrolment
- History of conditions known to producing immunodeficiency (Acquired Immune Deficiency Syndrome, other congenital immunodeficiency syndrome, drug therapy with steroids, anticancer drugs etc)
- Known hypersensitivity to Bacillus clausii or other probiotics.
- The above information is not intended to contain all considerations relevant to a patient's potential participation in a clinical trial.
Contact the study team to confirm eligibility.
Sponsors & Collaborators
- Sanofilead
Study Sites (1)
Sanofi-Aventis
Mumbai, India
MeSH Terms
Conditions
Interventions
Condition Hierarchy (Ancestors)
Intervention Hierarchy (Ancestors)
Study Officials
- STUDY DIRECTOR
Shah Pratik
Sanofi
Study Design
- Study Type
- interventional
- Phase
- phase 3
- Allocation
- RANDOMIZED
- Masking
- NONE
- Purpose
- TREATMENT
- Intervention Model
- PARALLEL
- Sponsor Type
- INDUSTRY
Study Record Dates
First Submitted
April 5, 2007
First Posted
April 6, 2007
Study Start
March 1, 2007
Primary Completion
December 1, 2007
Last Updated
January 21, 2009
Record last verified: 2009-01